

1 **Kinetics of neutralising antibodies against Omicron variant in**
2 **Vietnamese healthcare workers after primary immunisation with**
3 **ChAdOx1-S and booster with BNT162b2**

4 Nguyen Van Vinh Chau^{1,2} Lam Anh Nguyet³, Nguyen Thanh Dung⁴, Vo Minh Quang⁴,
5 Nguyen Thanh Truong⁵, Le Mau Toan⁴, Le Manh Hung⁴, Dinh Nguyen Huy Man⁴, Dao
6 Bach Khoa⁴, Nguyen Thanh Phong⁴, Nghiem My Ngoc⁴, Huynh Phuong Thao⁴, Dinh Thi
7 Bich Ty⁴, Pham Ba Thanh⁴, Nguyen Thi Han Ny³, Le Kim Thanh³, Cao Thu Thuy³,
8 Nguyen To Anh³, Nguyen Thi Thu Hong³, Le Nguyen Truc Nhu³, Lam Minh Yen³, Guy
9 Thwaites^{2,3}, Tran Tan Thanh³, and Le Van Tan^{2,3}, for OUCRU COVID-19 Research
10 Group*

11 ¹Department of Health, Ho Chi Minh City, Vietnam

12 ²Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
13 University of Oxford, Oxford, UK

14 ³Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

15 ⁴Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

16 ⁵Tan Phu Hospital, Ho Chi Minh City, Vietnam

17 *Members of the groups are listed in the acknowledgments.

18 Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, and Le Van Tan,
19 tanlv@oucru.org

20 **Word count: abstract:** 250 word, **Main text:** 2401 words

21 **Running title:** Neutralization of SARS-CoV-2 Omicron variant

22 **Keywords:** COVID-19, SARS-CoV-2, Omicron, vaccine, pandemic, Vietnam

23 **Abstract**

24 We studied the development and persistence of neutralising antibodies against SARS-
25 CoV-2 ancestral strain, and Delta and Omicron (BA.1 and BA.2) variants in Vietnamese
26 healthcare workers (HCWs) up to 15 weeks after booster vaccination. We included 47
27 HCWs with different pre-existing immune statuses (group 1 (G1): n=21, and group 2
28 (G2): n=26 without and with prior breakthrough Delta variant infection, respectively).
29 The study participants had completed primary immunisation with ChAdOx1-S and
30 booster vaccination with BNT162b2. Neutralising antibodies were measured using a
31 surrogate virus neutralisation assay. Of the 21 study participants in G1, neutralising
32 antibodies against ancestral strain, Delta variant, BA.1 and BA.2 were (almost) abolished
33 at month 8 after the second dose, but all had detectable neutralising antibodies to the
34 study viruses at week two post booster dose. Of the 26 study participants in G2,
35 neutralising antibody levels to BA.1 and BA.2 were significantly higher than those to the
36 corresponding viruses measured at week 2 post breakthrough infection and before the
37 booster dose. At week 15 post booster vaccination, neutralising antibodies to BA.1 and
38 BA.2 dropped significantly, with more profound changes observed in those without
39 breakthrough Delta variant infection. Booster vaccination enhanced neutralising activities
40 against ancestral strain and Delta variant, as compared to those induced by primary
41 vaccination. These responses were maintained at high levels for at least 15 weeks. Our
42 findings emphasise the importance of the first booster dose in producing cross-
43 neutralising antibodies against Omicron variant. A second booster dose might be needed
44 to maintain long-term protection against Omicron variant.

45 INTRODUCTION

46 COVID-19 vaccine induced immunity wanes [1, 2], which has led to the administration
47 of booster doses worldwide. Follow-up studies assessing the impact of booster
48 vaccination on the development and persistence of the immune response to SARS-CoV-2
49 and circulating variants of concern (VOC) remain critical to informing the allocation of
50 resources, policy decisions on COVID-19 mitigation measures, and the development of
51 next-generation vaccines [3].

52 Over the last 12 months, SARS-CoV-2 Delta and Omicron VOCs have been responsible
53 for two consecutive COVID-19 waves globally. Omicron variant is genetically divided
54 into five major sublineages: BA.1-5. Earlier in 2022, BA.2 replaced BA.1 to become the
55 dominant variant worldwide, including in Vietnam [4]. As of June 13th 2022, BA.4 and
56 BA.5 were responsible for the most recent waves in South Africa and Portugal [5, 6] with
57 spread reported into Europe and the USA [7].

58 It is thus critical to assess levels of neutralising antibodies induced by primary course and
59 booster vaccination against Delta and Omicron variants, especially in individuals with
60 different pre-existing immunity; e.g. breakthrough and non-breakthrough infection. Yet,
61 most of the reported data have been from high income countries [8-14], and few studies,
62 especially those focusing on long term immunity, have been conducted in low- and
63 middle-income countries.

64 Vietnam started the national COVID-19 vaccination programme in March 2021, and
65 introduced the first boosters in December 2021. Herein, we focused our analysis on
66 health care workers (HCWs) of the Hospital for Tropical Diseases (HTD) in Ho Chi
67 Minh City (HCMC), Vietnam. Our aim was to assess the impact of the heterologous

68 booster on the development and persistence of neutralising antibodies against the
69 ancestral strain, Delta and Omicron variants (BA.1 and BA.2), in HTD staff with and
70 without prior breakthrough infection.

71 **MATERIALS AND METHODS**

72 **Setting and the vaccine evaluation study**

73 The present study has been conducted at HTD in HCMC since March 2021 [15]. HTD is
74 a 550-bed tertiary referral hospital for patients with infectious diseases in southern
75 Vietnam. HTD has around 900 members of staff, and has been responsible for receiving
76 COVID-19 patients of all severities in Southern Vietnam since the beginning of the
77 pandemic.

78 The detailed descriptions about the study cohort have previously been reported [15]. In
79 brief, a total of 554 individuals were enrolled at baseline, and 144 were selected for
80 followed up from the second dose onward. Two doses of Oxford-AstraZeneca COVID-19
81 vaccine (ChAdOx1-S) were given as part of the primary course, completed by the first
82 week of May 2021. And Pfizer-BioNTech COVID-19 vaccine (BNT162b2) was given as
83 part the booster dose, completed in the third week of December 2021.

84 **Weekly SARS-CoV-2 testing**

85 As per the national COVID-19 control strategy in Vietnam, between June 2021 and
86 March 2022, HTD staff were tested weekly for SARS-CoV-2 using either PCR or antigen
87 tests [16]. When available, samples were subjected to SARS-CoV-2 whole-genome
88 sequencing to determine SARS-CoV-2 variant [17]. This allowed for the detection of
89 breakthrough infection. We previously reported a cluster of breakthrough Delta variant

90 infection among HTD staff members in June 2021 [18]. Any staff members with
91 breakthrough infection requiring hospitalisation was admitted to HTD for clinical care.

92 **Plasma samples for antibody measurement**

93 We selected 47 HCWs from the original vaccine evaluation study, consisting of group 1
94 (G1) including 21 without documented breakthrough infection from baseline until booster
95 vaccination, and group 2 (G2), including 26 with breakthrough Delta variant infection
96 [15]. More detailed descriptions about the selected participants and sampling schedules
97 are presented in Figure 1.

98 **Sample size justification**

99 The 47 HCWs were selected for analysis because they had longitudinal plasma samples
100 collected from dose 2 (G1) or breakthrough infection (G2) until month 3 after the booster
101 dose. Sampling at this scale however has been proven to be sufficient to demonstrate the
102 differences in antibody responses to Omicron variant in people receiving either
103 heterologous or homologous BNT162b2 booster vaccination [13].

104 **Antibody measurements**

105 For measurement of neutralizing antibodies against SARS-CoV-2 original strain (herein
106 referred as ancestral) and SARS-CoV-2 Delta and Omicron variants (BA.1 and BA.2),
107 we used the SARS-CoV-2 Surrogate Virus Neutralization (sVNT) assay (Genescript,
108 USA). sVNT is a blocking ELISA that quantifies neutralizing antibodies targeting the
109 receptor binding domain (RBD) of S protein [19]. The experiments were carried as per
110 the manufacturers' instructions with the readouts expressed as percentage of inhibition.

111 **Statistical analysis**

112 The Wilcoxon signed-rank test or the paired T-test was used to compare the differences
113 in neutralizing antibody levels to ancestral strain, Delta, BA.1 and BA.2 between and
114 within groups when appropriate. The Spearman's correlation was used to assess the
115 correlation of neutralizing antibody levels and age. All analyses were performed using
116 GraphPad Prism 9.3.1 (GraphPad Software, La Jolla, CA, USA).

117 **Ethics**

118 The study received approvals from the Institutional Review Board of the Hospital for
119 Tropical Diseases in Ho Chi Minh City Vietnam and the Oxford Tropical Research
120 Ethics Committee. Written informed consent was obtained from all the study participants.

121 **RESULTS**

122 **Demographics and breakthrough infection after booster vaccination**

123 Information about the demographics and vaccination status of the selected participants
124 are presented in Table 1 and Figure 1. The window time between the second dose and the
125 booster dose was around 8 months. Of the 26 participants in G2, the window time from
126 infection to booster vaccination was around 6 months (Figure 1).

127 During the follow up, 9 individuals, including 5/21 (24%) participants of G1 and 4/26
128 (15%) participants of G2, had a SARS-CoV-2 infection episode recorded after the
129 booster dose (Figure 1). Although detailed clinical descriptions were not available, no
130 hospitalisation was reported, suggesting that all were either asymptomatic or mildly
131 symptomatic. E-gene real time PCR Ct values were available in two samples of G1 (13.1
132 and 15.4). Of these, information about SARS-CoV-2 variant was available in one; which
133 was assigned to BA.2. The window time (median in days) from infection to blood

134 sampling at month three after booster vaccination was 28 (range: 12-103) for G1 and 17
135 (range: 8-22) for G2.

136 **Neutralising antibodies against BA.1 and BA.2 after primary vaccination with**
137 **ChAdOx1-S**

138 Of the 21 participants in G1, at week two after the primary course, detectable neutralising
139 antibodies against ancestral strain and Delta variant were documented in 21 (100%) and
140 20 (95%), with comparable levels to ancestral strain and Delta variant (Figure 2A and
141 Table 2). Neutralising antibodies to BA.2 were not detected, while neutralising antibodies
142 against BA.1 were detected in only 3 participants but the titers approached the detection
143 limit of the sVNT assay (Figure 2A and Table 2).

144 **Development of neutralising antibodies after heterologous booster with BNT162b2**
145 **in individual with and without prior breakthrough infection**

146 Of the 21 participants in G1, before the booster dose (i.e. month 8 after dose 2), none had
147 detectable neutralising antibodies against Omicron variant (BA.1 and BA.2). The
148 proportions of individuals with detectable neutralising antibodies to the ancestral strain
149 and Delta variant were 8/21 (38%) and 2/21 (10%), respectively, with neutralising titers
150 approaching the assay detection limit (Figure 2A). At week 2 after the booster dose, all
151 had neutralising antibodies against ancestral strain and VOCs (Delta, BA.1 and BA.2).
152 Notably neutralising antibody levels to ancestral strain, and Delta variant measured at 2
153 weeks after the booster dose were significantly higher than those to the respective viruses
154 measured at week 2 after dose 2 (median inhibition in % (interquartile range (IQR)): for
155 ancestral strain: 97.3 (96.9-97.5) vs. 86.2 (74.6-93.8), $p < 0.001$, and for Delta variant:
156 98.2 (98.0-98.3) vs. 86.3 (74.4-89.8), $p < 0.001$) (Figure 2A). Neutralising antibody levels

157 to BA.2 were significantly higher than those to BA.1 (median inhibition in % (IQR): 92.7
158 (89.2-95.6) vs. 84.1 (74.1-90.6), $p < 0.001$) (Figure 2A and Table 2).

159 Of the 26 participants in G2, neutralising antibodies against ancestral strain, Delta, BA.1
160 and BA.2 measured at week 2 after breakthrough infection were detectable in 24 (92%),
161 23 (88%), 18 (69%) and 17 (65%), respectively (Figure 2B), with neutralising antibody
162 levels to the ancestral strain and Delta variant significantly higher than those to BA.1 and
163 BA.2 (Figure 2B and Table 2). At week 2 after booster vaccination, neutralising antibody
164 levels to BA.1 and BA.2 significantly increased as compared to those measured before
165 the booster dose and at 2 weeks post breakthrough infection, but remained significantly
166 lower than those against ancestral strain and Delta variant (Figure 2B and Table 2). At
167 this time point, neutralising antibody levels to BA.2 were significantly higher than those
168 to BA.1 (median inhibition in % (IQR): 95.7 (90.8-97.7) vs. 92.3 (82.8-95.7), $p < 0.004$)
169 (Figure 2B).

170 **Persistence of neutralising antibodies at week 15 after booster vaccination**

171 To assess the persistence of neutralising antibodies induced by the booster dose, we first
172 focused our analysis on those without a SARS-CoV-2 infection episode documented after
173 booster vaccination. At week 15 after the booster dose, of 16 study participants in G1, 16
174 (100%) had detectable neutralising antibodies against ancestral, Delta and BA.2 variants,
175 while 11/16 (69%) had detectable neutralising antibodies against BA.1. Accordingly,
176 neutralising antibody levels to BA.1 and BA.2 was significantly lower compared to those
177 measured at week 2 post booster vaccination (median inhibition in % (IQR): for BA.1:
178 54.3 (19.1-92.1) vs. 85.7 (71.3-92.1), $p = 0.034$, and for BA.2: 83.7 (68.3-97.6) vs. 93.2

179 (90.4-95.7), $p=0.034$) (Figure 3A). Neutralising antibodies against Delta variant also
180 slightly reduced, but remained at very high titers (Figure 3A).

181 Of the 22 participants without a SARS-CoV-2 infection episode documented after the
182 booster dose in G2, neutralising antibody levels to BA.1 significantly decreased (median
183 inhibition in % (IQR): 87.8 (70.5-93.2) vs. 92.3 (82.5-95.8), $p=0.012$) (Figure 3B).

184 Otherwise, neutralising antibody levels to ancestral strain, Delta and BA.2 measured at
185 this time points were comparable with those of the corresponding viruses measured at
186 two weeks post booster dose (Figure 3B and Table 2).

187 Of the nine individuals with a documented SARS-COV-2 infection episode after the
188 booster dose, neutralising antibody levels to ancestral strain and all VOCs slightly
189 increased at week 15, albeit not statistically significant in case of ancestral strain, BA.1
190 and BA.2 (Supplementary Figure 1).

191 **Association between age and neutralising antibody levels to BA.1 and BA.2**

192 Results of linear regression analysis showed no association between age and neutralizing
193 antibodies levels to BA.1 and BA.2 measured at week 2 and week 15 post booster dose
194 (Supplementary Figure 2). Similar analysis for ancestral strains and Delta variant was
195 considered uninformative because neutralising antibody levels to these two viruses in all
196 study participants reached the upper detection limit of the assay (100%) (Figure 3).

197 **DISCUSSION**

198 We showed that neutralising antibodies induced by primary immunization with
199 ChAdOx1-S in Vietnamese HCWs failed to neutralize Omicron variant BA.1 and BA.2.
200 Heterologous booster vaccination with BNT162b2 improved the immunity that could
201 broadly neutralize both BA.1 and BA.2 in HCWs with and without prior breakthrough

202 infection. Additionally, booster vaccination significantly enhanced neutralising antibody
203 levels to the ancestral strain and Delta variant. However, neutralising antibodies against
204 BA.1 and BA.2 significantly declined at month 3 post-booster vaccination, particularly in
205 those without breakthrough infection, while neutralising antibodies to ancestral strain and
206 Delta variant remained at high titers. We found no association between age and
207 neutralising antibody levels, in line with a recent report [12], but none of our study
208 participants were older than 57 years. Our findings are consistent with existing data
209 regarding the capacity of the Omicron variant to escape from neutralizing antibodies
210 induced by vaccination [10, 20]. The results also support previous findings about the
211 effectiveness of the third doses in preventing infection, severe disease and death [14].

212 Over half of the plasma samples collected at two weeks after breakthrough Delta variant
213 infection cross-neutralised BA.1 and BA.2, supporting recent reports regarding protection
214 against Omicron offered by previous infection [21-23]. Booster vaccination further
215 enhanced the cross-neutralising activities and the proportion of plasma samples with
216 detectable neutralizing antibodies in these individuals with breakthrough Delta variant
217 infection 6 months earlier [18]. Because neutralising antibodies titers are well correlated
218 with protection [24, 25], the data suggest that booster vaccination could still be beneficial
219 to individuals with breakthrough infection in protecting against Omicron variant [21, 23].

220 Likewise, the decline in neutralising antibody levels to sublineages BA.1 and BA.2 at
221 week 15 after the first booster dose suggest that a second booster doses might be needed
222 to maintain the long-term protection of vaccine against Omicron variant [12]. Our results
223 also compliment findings from a recent population based study in the USA [2], which
224 showed that during the Omicron wave vaccine effectiveness against hospitalizations

225 dropped from 91% during the first 2 months to 78% \geq 4 months after a third dose.
226 Additionally, a recent study from Israel demonstrated that a second booster dose of the
227 BNT162b2 vaccine was effective in reducing the risk of COVID-19 associated outcomes
228 (including infection) in individuals already completing the first booster dose at least 4
229 months earlier [9].

230 Our study consistently showed that neutralising antibody tiers against BA.2 after the
231 booster dose in individuals with and without prior breakthrough infection were
232 significantly higher than those against BA.1. Relevant data from previous studies have so
233 far been inconsistent. Recent studies from Germany and Hong Kong showed comparable
234 serum neutralising antibody levels to BA.1 and BA.2 in individuals completing three
235 doses of BNT162b2 [8, 26]. In contrast, Yu and colleagues showed that median
236 neutralising antibody titers against BA.2 was lower than those against BA.1 in people
237 triple vaccinated with BNT162b2, and in those with previous infection regardless of the
238 vaccination status [11]. The differences in study populations and pre-existing immunity
239 induced by past exposure and/or vaccination might be contributing factors. Whether
240 BA.2 is less able to evade immunity than BA.1 merits further research.

241 Our study has several limitations. First, we did not perform live virus neutralisation
242 assay, currently the gold standard, to measure neutralising antibodies. However, the
243 percentage of inhibition measured by the sVNT test has been shown to correlate well
244 with the neutralizing antibody titers measured by the conventional plaque reduction
245 neutralization assay [19]. Second, we did not study T-cell responses, which have been
246 proven to play an important role in protecting against severe disease and death, and in

247 case of Omicron variant, despite the neutralisation escape, T-cell responses were
248 preserved at around 70-80% [27, 28].

249 In summary, we showed that booster vaccination by BNT162b2 induced cross-
250 neutralising activities against sublineages BA.1 and BA.2 of Omicron variant in
251 Vietnamese HCWs completing primary immunization with ChAdOx1-S. These responses
252 however significantly reduced at month 3 post booster doses, indicating a second booster
253 is potentially needed to maintain long-term vaccine effectiveness against the currently
254 circulating variants. Vaccines remains critical to reduce the transmission and to protect
255 against severe disease and death.

256 **ACKNOWLEDGEMENTS**

257 This study was funded by the Wellcome Trust of Great Britain (106680/B/14/Z,
258 204904/Z/16/Z and 222574/Z/21/Z).

259 We thank our colleagues at the Hospital for Tropical Diseases in Ho Chi Minh City,
260 Vietnam, for their participations in this study.

261 OUCRU Vietnam COVID-19 research group: Chambers Mary, Choisy Marc, Day
262 Jeremy, Dong Huu Khanh Trinh, Dong Thi Hoai Tam, Du Hong Duc, Dung Vu Tien
263 Viet, Fisher Jaom, Flower Barney, Geskus Ronald, Hang Vu Thi Kim, Ho Quang Chanh,
264 Ho Thi Bich Hai, Ho Van Hien, Hung Vu Bao, Huong Dang Thao, Huynh le Anh Huy,
265 Huynh Ngan Ha, Huynh Trung Trieu, Huynh Xuan Yen, Kestelyn Evelyne, Kesteman
266 Thomas, Lam Anh Nguyet, Lawson Katrina, Leigh Jones, Le Kim Thanh, Le Dinh Van
267 Khoa, Le Thanh Hoang Nhat, Le Van Tan, Lewycka Sonia Odette, Lam Minh Yen, Le
268 Nguyen Truc Nhu, Le Thi Hoang Lan, Nam Vinh Nguyen, Ngo Thi Hoa, Nguyen Bao
269 Tran, Nguyen Duc Manh, Nguyen Hoang Yen, Nguyen Le Thao My, Nguyen Minh
270 Nguyet, Nguyen To Anh, Nguyen Thanh Ha, Nguyen Than Ha Quyen, Nguyen Thanh
271 Ngoc, Nguyen Thanh Thuy Nhien, Nguyen Thi Han Ny, Nguyen Thi Hong Thuong,
272 Nguyen Thi Hong Yen, Nguyen Thi Huyen Trang, Nguyen Thi Kim Ngoc, Nguyen Thi
273 Kim Tuyen, Nguyen Thi Ngoc Diep, Nguyen Thi Phuong Dung, Nguyen Thi Tam,
274 Nguyen Thi Thu Hong, Nguyen Thu Trang, Nguyen Thuy Thuong Thuong, Nguyen
275 Xuan Truong, Nhung Doan Phuong, Ninh Thi Thanh Van, Ong Phuc Thinh, Pham Ngoc
276 Thanh, Phan Nguyen Quoc Khanh, Phung Ho Thi Kim, Phung Khanh Lam, Phung Le
277 Kim Yen, Phung Tran Huy Nhat, Rahman Motiur, Thuong Nguyen Thi Huyen, Thwaites
278 Guy, Thwaites Louise, Tran Bang Huyen, Tran Dong Thai Han, Tran Kim Van Anh,
279 Tran Minh Hien, Tran Phuong Thao, Tran Tan Thanh, Tran Thi Bich Ngoc, Tran Thi
280 Hang, Tran Tinh Hien, Trinh Son Tung, van Doorn H. Rogier, Van Nuil Jennifer,

281 Vidailiac Celine Pascale, Vu Thi Ngoc Bich, Vu Thi Ty Hang, Yacoub Sophie. HTD
282 COVID-19 research group: Nguyen Van Vinh Chau, Nguyen Thanh Dung, Le Manh
283 Hung, Huynh Thi Loan, Nguyen Thanh Truong, Nguyen Thanh Phong, Dinh Nguyen
284 Huy Man, Nguyen Van Hao, Duong Bich Thuy, Nghiem My Ngoc, Nguyen Phu Huong
285 Lan, Pham Thi Ngoc Thoa, Tran Nguyen Phuong Thao, Tran Thi Lan Phuong, Le Thi
286 Tam Uyen, Tran Thi Thanh Tam, Bui Thi Ton That, Huynh Kim Nhung, Ngo Tan Tai,
287 Tran Nguyen Hoang Tu, Vo Trong Vuong, Dinh Thi Bich Ty, Le Thi Dung, Thai Lam
288 Uyen, Nguyen Thi My Tien, Ho Thi Thu Thao, Nguyen Ngoc Thao, Huynh Ngoc Thien
289 Vuong, Huynh Trung Trieu, Pham Ngoc Phuong Thao, Phan Minh Phuong. EOCRU
290 COVID-19 research group: Bachtiar, Andy, Baird, Kevin J., Dewi, Fitri, Dien, Ragil,
291 Djaafara, Bimandra A., Elyazar, Iqbal E., Hamers, Raph L., Handayani, Winahyu,
292 Kurniawan, Livia Nathania, Limato, Ralalicia, Natasha, Cindy, Nuraeni, Nunung,
293 Puspatriani, Khairunisa, Rahadjani, Mutia, Rremainar, Atika, Saraswati, Shankar, Anuraj
294 H., Suhendra, Henry, Sutrisni, Ida Ayu, Suwarti, Tarino, Nicolas, Timoria, Diana,
295 Wulandari, Fitri. OUCRU-NP COVID-19 research group: Basnyat Buddha, Duwal
296 Manish, Gautum Amit, Karkey Abhilasha, Kharel Niharika, Pandey Aakriti, Rijal Samita,
297 Shrestha Suchita, Thapa Pratibha, Udas Summita.
298

299 REFERENCES

- 300 1. Goldberg, Y., et al., *Waning Immunity after the BNT162b2 Vaccine in Israel*. N
301 Engl J Med, 2021. **385**(24): p. e85.
- 302 2. Ferdinands, J.M., et al., *Waning 2-Dose and 3-Dose Effectiveness of mRNA*
303 *Vaccines Against COVID-19-Associated Emergency Department and Urgent*
304 *Care Encounters and Hospitalizations Among Adults During Periods of Delta and*
305 *Omicron Variant Predominance - VISION Network, 10 States, August 2021-*
306 *January 2022*. MMWR Morb Mortal Wkly Rep, 2022. **71**(7): p. 255-263.
- 307 3. Magen, O., et al., *Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a*
308 *Nationwide Setting*. New England Journal of Medicine, 2022.
- 309 4. <https://nextstrain.org/ncov/gisaid/global/6m>. Accessed on 14 June 2022.
- 310 5. Tegally, H., et al., *Continued Emergence and Evolution of Omicron in South*
311 *Africa: New BA.4 and BA.5 lineages*. MedRxiv, 2022.
- 312 6. National Institute of Health. *Monitoring of COVID-19 in Portugal*. 2022
313 Available at: [https://www.insa.min-](https://www.insa.min-saude.pt/wp-content/uploads/2022/06/20220601_Monitorizacao_COVID-19.pdf)
314 [saude.pt/wp-](https://www.insa.min-saude.pt/wp-content/uploads/2022/06/20220601_Monitorizacao_COVID-19.pdf)
[content/uploads/2022/06/20220601_Monitorizacao_COVID-19.pdf](https://www.insa.min-saude.pt/wp-content/uploads/2022/06/20220601_Monitorizacao_COVID-19.pdf).

- 315 7. Stockholm, E., *European Centre for Disease Prevention and Control.*
316 *Implications of the emergence and spread of the SARS-CoV-2 variants of concern*
317 *BA.4 and BA.5 for the EU/EEA – 14 June 2022.* 2022.
- 318 8. Arora, P., et al., *Comparable neutralisation evasion of SARS-CoV-2 omicron*
319 *subvariants BA.1, BA.2, and BA.3.* *The Lancet Infectious Diseases*, 2022. **22**(6):
320 p. 766-767.
- 321 9. Magen, O., et al., *Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a*
322 *Nationwide Setting.* *N Engl J Med*, 2022. **386**(17): p. 1603-1614.
- 323 10. Hu, J., et al., *Increased immune escape of the new SARS-CoV-2 variant of*
324 *concern Omicron.* *Cellular & Molecular Immunology*, 2022. **19**(2): p. 293-295.
- 325 11. Yu, J., et al., *Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.*
326 *N Engl J Med*, 2022. **386**(16): p. 1579-1580.
- 327 12. Lassauniere, R., et al., *Neutralizing Antibodies Against the SARS-CoV-2 Omicron*
328 *Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2*
329 *mRNA Vaccine.* *JAMA Netw Open*, 2022. **5**(5): p. e2212073.
- 330 13. Cheng, S.M.S., et al., *Neutralizing antibodies against the SARS-CoV-2 Omicron*
331 *variant BA.1 following homologous and heterologous CoronaVac or BNT162b2*
332 *vaccination.* *Nat Med*, 2022. **28**(3): p. 486-489.
- 333 14. Lustig, Y., et al., *Superior immunogenicity and effectiveness of the 3rd BNT162b2*
334 *vaccine dose.* *MedRxiv*, 2021.
- 335 15. Chau, N.V.V., et al., *Immunogenicity of Oxford-AstraZeneca COVID-19 Vaccine*
336 *in Vietnamese Health-Care Workers.* *Am J Trop Med Hyg*, 2022. **106**(2): p. 556-
337 561.
- 338 16. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-*
339 *time RT-PCR.* *Euro Surveill*, 2020. **25**(3).
- 340 17. Chau, N.V.V., et al., *Rapid whole-genome sequencing to inform COVID-19*
341 *outbreak response in Vietnam.* *J Infect*, 2021. **82**(6): p. 276-316.
- 342 18. Chau, N.V.V., et al., *An observational study of breakthrough SARS-CoV-2 Delta*
343 *variant infections among vaccinated healthcare workers in Vietnam.*
344 *EClinicalMedicine*, 2021. **41**: p. 101143.

- 345 19. Tan, C.W., et al., *A SARS-CoV-2 surrogate virus neutralization test based on*
346 *antibody-mediated blockage of ACE2-spike protein-protein interaction.* Nat
347 Biotechnol, 2020. **38**(9): p. 1073-1078.
- 348 20. Dejnirattisai, W., et al., *SARS-CoV-2 Omicron-B.1.1.529 leads to widespread*
349 *escape from neutralizing antibody responses.* Cell, 2022. **185**(3): p. 467-484 e15.
- 350 21. Smid, M., et al., *Protection by vaccines and previous infection against the*
351 *Omicron variant of SARS-CoV-2.* J Infect Dis, 2022.
- 352 22. Altarawneh, H.N., et al., *Protection against the Omicron Variant from Previous*
353 *SARS-CoV-2 Infection.* N Engl J Med, 2022. **386**(13): p. 1288-1290.
- 354 23. Nyberg, T., et al., *Comparative analysis of the risks of hospitalisation and death*
355 *associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants*
356 *in England: a cohort study.* The Lancet, 2022. **399**(10332): p. 1303-1312.
- 357 24. Gilbert, P.B., et al., *Immune correlates analysis of the mRNA-1273 COVID-19*
358 *vaccine efficacy clinical trial.* Science, 2022. **375**(6576): p. 43-50.
- 359 25. Fong, Y., et al., *Immune Correlates Analysis of a Single Ad26.COV2.S Dose in*
360 *the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.* medRxiv, 2022.
- 361 26. Chen, L.L., et al., *Serum neutralisation of the SARS-CoV-2 omicron sublineage*
362 *BA.2.* Lancet Microbe, 2022. **3**(6): p. e404.
- 363 27. Gao, Y., et al., *Ancestral SARS-CoV-2-specific T cells cross-recognize the*
364 *Omicron variant.* Nat Med, 2022. **28**(3): p. 472-476.
- 365 28. Tarke, A., et al., *SARS-CoV-2 vaccination induces immunological T cell memory*
366 *able to cross-recognize variants from Alpha to Omicron.* Cell, 2022. **185**(5): p.
367 847-859 e11.
368

369 **LEGENDS TO FIGURES**

370 **Figure 1:** Illustration showing the distribution of the study participants and sampling
371 schedules for neutralising antibody measurement

372 **Figure 2:** Neutralizing antibodies against SARS-CoV-2 ancestral strain and VOCs
373 (Delta, BA.1 and BA.2) in individuals without (A) and with (B) documented prior
374 breakthrough Delta variant infection measured at different time points prior to booster
375 vaccination and at week 2 post booster dose. Horizontal dot lines indicate assay cut-off.
376 Numbers indicates p values.

377 **Figure 3:** Persistence of neutralising antibodies at month 3 after the booster dose in those
378 without documented breakthrough infection after the booster dose, **A)** participants of G1,
379 and **B)** participants of G2. Horizontal dot lines indicate assay cut-off, Numbers indicates
380 p values.

Table 1: Demographics and time intervals between vaccine doses

Variables	G1: HCWs without documented breakthrough infection prior to booster vaccination (n=21)	G2: HCWs with breakthrough infection prior to booster vaccination, (n=26)
Male gender, n (%)	1 (4.8)	10 (38.5)
Age year, median (range)	35 (24-54)	40.5 (24-56)
Vaccine dose 1 date (range)	8-12 Mar/2021	8-15 Mar/2021
Vaccine dose 2 date (range)	19-28 Apr/2021	22 Apr - 4 May/2021
Vaccine dose 3 date (range)	16-17 Dec/2021	16-21 Dec/2021
Days from vaccine dose 1 to dose 2, median (range)	43 (40-49)	44 (39-53)
Days from vaccine dose 2 to dose 3, median (range)	238 (233-241)	238 (231-245)
Days from vaccine dose 3 to breakthrough infection, median (range)	NA	187 (184-191)
Breakthrough infection after booster dose, n (%)	5 (23.8)	4 (15.4)
Days from booster vaccination to infection, median (range)	82 (1-94)	86 (77-96)
Days from infection after booster dose to blood sampling, median (range)	28 (12-103)	17 (8-22)

Note to Table 1: NA: Non-applicable

Table 2: Neutralising antibody levels to ancestral strain, Delta variant, BA.1 and BA.2 measured at four time points during the study period

		Ancestral strain	Delta variant	BA.1	BA.2
G1: HCWs without prior breakthrough infection	2 weeks after dose 2	86.2 (74.6-93.8)	86.3 (74.4-89.8)	-4.7 (-12-9.5)	6.1 2.9-14.4)
	Before dose 3	26.9 (19.1-36.2)	7.5 (-5.3-17.5)	-3.2 (-5.5-1)	0 (0-3.3)
	2 weeks after dose 3	97.3 (96.9-97.5)	98.2 (98.0-98.3)	84.1 (74.1-90.6)	92.7 (89.2-95.6)
	15 weeks after dose 3	97.5 (97.4-97.6)	97.9 (97.4-98.1)	54.3 (19.1-92.1)	83.7 (68.3-97.6)
G2: HCWs with prior breakthrough infection	2 weeks after breakthrough infection	96.9 (81.6-97.0)	97.6 (77.2-98.2)	70.0 (10.9-80.8)	85.7 (-5.2-92.4)
	Before dose 3	96.0 (87.8-96.6)	97.5 (71.9-98)	18.8 (6-46.7)	74.1 (34.5-82.9)
	2 weeks after dose 3	96.1 (95.8-97.5)	98.1 (98.0-98.4)	92.3 (82.8-95.7)	95.7 (90.8-97.7)
	15 weeks after dose 3	96.8 (96.7-97.0)	98 (98.0-98.2)	87.8 (70.5-93.2)	94.9 (89.0-98.2)

Note to Table 2: Reported values are median inhibition in % (interquartile range)




Figure 1: Illustration showing the distribution of the study participants and sampling schedules for neutralising antibody measurement
Note to Figure 1: *after excluding cases with a SARS-CoV-2 infection episode recorded after the booster dose.




Figure 2: Neutralizing antibodies against SARS-CoV-2 ancestral strain and VOCs (Delta, BA.1 and BA.2) in individuals with and without prior breakthrough Delta variant infection measured at different time points prior to booster vaccination and at week 2 post booster dose. Horizontal dot lines indicate assay cut-off. Numbers indicates p values.




Figure 3: Persistence of neutralising antibodies at month 3 after the booster dose in those without documented breakthrough infection after the booster dose, **A**) participants of G1, and **B**) participants of G2. Horizontal dot lines indicate assay cut-off, Numbers indicates p values.

381 **Supplementary Materials For**

382 **Kinetics of neutralising antibodies against Omicron variant in**
383 **Vietnamese healthcare workers after primary immunisation with**
384 **ChAdOx1-S and booster with BNT162b2**

385 Nguyen Van Vinh Chau¹, Lam Anh Nguyet², Nguyen Thanh Dung³, Nguyen Thanh
386 Truong⁴, Le Mau Toan³, Le Manh Hung³, Dinh Nguyen Huy Man³, Nghiem My Ngoc³,
387 Huynh Phuong Thao³, Dinh Thi Bich Ty³, Pham Ba Thanh³, Nguyen Thi Han Ny², Le
388 Kim Thanh², Cao Thu Thuy², Nguyen To Anh², Nguyen Thi Thu Hong², Le Nguyen Truc
389 Nhu², Lam Minh Yen², Guy Thwaites^{2,5}, Tran Tan Thanh², and Le Van Tan², for
390 OUCRU COVID-19 Research Group*

391 ¹Department of Health, Ho Chi Minh City, Vietnam

392 ²Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam


393 ³Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam

394 ⁴Tan Phu Hospital, Ho Chi Minh City, Vietnam


395 ⁵Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
396 University of Oxford, Oxford, UK

397 *Members of the groups are listed in the acknowledgments.

398 Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, and Le Van Tan,
399 tanlv@oucru.org



Supplementary Figure 1: Neutralising antibodies measured at week 2 and 15 after booster vaccination in 11 HCWs with an infection episode documented after the booster dose



Supplementary Figure 2: Association between age and neutralising antibody levels to BA.1 and BA.2 measured at week 2 and 15 post booster vaccination in those without a SARS-CoV-2 infection episode recorded after the booster dose, A) 16 individuals of G1 and B) 22 individuals of G2

Note to Supplementary Figure 2: rho: Spearman's rank correlation coefficient